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Abstract
Background: Facioscapulohumeral dystrophy (FSHD) is a rare hereditary disease with
a prevalence of 2.03–6.8 per 100,000 individuals. FSHD is the third most common type
of muscular dystrophy after the Duchene muscular dystrophy and myotonic dystrophy.
To the best of our knowledge, the current case report is the first to report probable
FSHD case mainly diagnosed using clinico-pathological evidence from sub-Saharan
Africa (SSA).
Case Report: A 22-year-old right-handed male college student presented with
progressive proximal muscular weakness associated with wasting. The weakness
started from the bilateral facial muscles and progressively involved proximal upper and
lower limbs muscles associated with scapular winging, waddling gait, and bilateral foot
drops. His bulbar, sensory, autonomic, and cognitive systems were spared. Muscles
EMG showed myopathic patterns and normal serum CK. Muscle biopsy from affected
muscles showed variation in fiber size with groups of angular fibers, preserved fibers,
and hypertrophic fibers with marked fibrosis and adipose tissue replacement with no
apparent inflammation and necrosis which is consistent with pathological features
of muscular dystrophy. Considering the clinical semiology, physical findings, EMG
findings, and pathological findings diagnosis of FSHD of scapuloperoneal variant
was made. The patient was managed with analgesics, nutritional advice, and ankle
prosthesis for foot drops. Currently, the patient is in a similar condition with modest
improvement in his musculoskeletal pain complaints.
Conclusion: This case highlights the fact that a careful clinical evaluation with thorough
utilization of diagnostic investigations available at our disposal may support the
diagnosis of FSHD in resource-limited areas where the necessary genetic tests were
not available.
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1. Introduction
Facioscapulohumeral muscular dystrophy (FSHD) is a rare hereditary disease with a
prevalence of 2.03–6.8 per 100,000 individuals [1]. FSHD is the third most common type
of muscular dystrophy after the Duchene muscular dystrophy and myotonic dystrophy
[1, 2]. The pathology of FSHD is a result of an intricate interaction of genetics, involving
the protein product of the DUX4 gene and the chromosomal location and number of
repeats of the D4Z4 microsatellite. The result of this interaction is the inappropriate
expression of the DUX4 protein product; however, it is sporadic in 30% [1–3]. FSHD is
classified into two categories: FSHD 1 and FSHD 2 [1]. The vast majority (95%) of patients
meeting clinical criteria for FSHD will have FSHD1, while the remaining 5% constitute
for FSHD 2 [1].
The disease often onsets in the second decade of life; however, the onset during
infancy and adulthood have also been reported [4]. The muscular weakness initially
involves proximal muscles such as facial, shoulder girdle, and arm muscles and subse-
quently progresses downward to involve lower limb and pelvic girdle muscles; however,
FSHD relatively spares extra ocular, pharyngeal, lingual, respiratory, and the myocar-
dial muscles compared to other muscular dystrophies [1, 3, 5–8]. Diagnoses of FSHD
depends on the fulfillment of clinical criteria, genetic study, electromyographic (EMG),
and histopathological evidence [1, 2, 4–7, 9, 10]. To date, there is no proven disease-
modifying therapy for FSHD; however, supportive treatments such as nutritional advise,
spine alignment surgery, and ankle prosthesis could be beneficial to patients with FSHD
[1, 4, 10, 11]. To the best of our knowledge, this is the first case report on the diagnosis of
FSHD based on clinico–pathological pieces of evidence from sub-Saharan Africa (SSA).
2. Case Report
A 22-year-old male presented with progressive weakness and wasting (atrophy) of
muscles of the bilateral face, shoulder, arm, pelvic girdles, and distal limb over a four-
year period. In addition, he had associated atrophy of proximal muscles of shoulder and
pelvic girdles. Progressively, he developed difficulty in combing and washing his hair,
standing from a sitting position, and waddling gait. Furthermore, he reported severe
back and joint pain which worsened when he walked and relieved with rest due to
his Hyperlordosis. Otherwise, no mentation changes, cognitive impairment, bladder or
bowel complaint, and no bulbar dysfunction were reported. The patient had no family
history of similar illness, no previous history of tuberculosis treatment. He is a third-year
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university student but discontinued his education because of progressive extremities
weakness and gait abnormality. The patient lives with his mother and one younger
brother, both of whom are healthy. His father died when he was young, cause unknown.
General appearance was emaciated. Vital signs were normal. Atrophied shoulder
muscles, bilateral pectorals muscles, intercostal muscles, proximal arm and pelvic mus-
cles with relative preserved muscle bulk of bilateral forearm and bilateral scapular
winging were noted (Figures 1a and 1b). The patient had prominent lordosis and pos-
itive Gower sign. Neurological examination showed bilateral facial diplegia (Figure 1c),
atrophied muscles with a power of 3/4 in proximal muscles and 4/5 in distal muscles in
both upper limbs. Bilateral foot drop was noted. Reflexes, tone, sensory examination,
and plantar reflexes were normal. Routine investigations were normal. Serology tests
for HIV and HBSAg were negative. Creatinine kinase was normal. Echocardiography
(ECHO), electrocardiography (ECG), and nerve conduction test (NCS) were normal. Elec-
tromyography (EMG) showed myopathic patterns without features of active denervation
potentials (Figure 2). Muscle biopsy from affected muscles showed variation in fiber size
with groups of angular fibers, preserved fibers, and hypertrophic fibers with marked
fibrosis and adipose tissue replacement with no apparent inflammation and necrosis
which is consistent with the pathological features of muscular dystrophy (Figures 3a
and 3b).
a b c
Figure 1: (a) Image showing significant muscular atrophy of intercostal, pectoralis, arm, and shoulder girdle
muscles. (b) Image showing bilateral scapular winging while the patient extends his upper limbs. (c) Image
showing slim elongated face with modest facial diplegia.
Considering the clinical semiology and the physical, EMG, and pathological findings,
the diagnosis of FSHD of scapuloperoneal variant was made. A definitive diagnosis of
FSHD requires genetic study confirmingmutations in a SMCHD1 gene. However, genetic
studies were not available in Ethiopia and if at all available, are not affordable by the
patients. Therefore, we solely based the diagnosis of FSHD in our patient on the typical
clinical presentation, EMG findings, and histopathological evidence. The patient and his
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Figure 2: Electromyography (EMG) image showing small amplitude and duration Muscle Action Unit
Potential (MUAP) suggesting myopathic patterns.
a b
Figure 3: E&M muscle biopsy from affected muscles showed variation in fiber size with groups of angular
fibers, preserved fibers, and hypertrophic fibers with marked fibrosis and adipose tissue replacement with
no apparent inflammation and necrosis which is consistent with pathological features muscular dystrophy.
family were advised on the available treatment options and prognosis of the disease.
He was started with NSAIDs for his back pain and joint pain. In addition, nutritional
advice was given in order to improve his muscle bulk. Ankle prosthesis was prescribed
for his bilateral foot drop. Currently, the patient is in a similar condition with modest
improvement in his musculoskeletal pain complaints.
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3. Comments
We present a young male who presented with progressive proximal muscular weakness
and wasting. The weakness started from the bilateral facial muscles and progressively
involved proximal upper and lower limbs muscles associated with scapular winging,
waddling gait, and bilateral foot drops. His bulbar, sensory, autonomic, and cognitive
systems were spared. Muscles EMG showed myopathic patterns and normal serum CK,
and histopathological examination from affected muscles revealed muscular dystrophy.
His overall evaluation suggested FSHD. Since genetic tests were not done, FSHD clas-
sification was not settled. The patient was managed symptomatically. FSHD commonly
occurs in the second or third decade of life [5]. Our patient is a 22-year-old male, which,
in line with the typical age of FSHD symptoms onset. We did conduct a genetic study
of our patient because of the unavailability of genetic tests. Despite the absence of
a positive family FSHD history in our patient, the fact that his father died of unknown
cause could remotely support the underlying genetic etiology. However, nearly 30% of
FSHD patients could be sporadic [12].
Accurate diagnosis of FSHD requires presences of hallmark clinical semiology such as
proximal onset muscle weakness and wasting (facial diplegia) and progressive involve-
ment of shoulder, pelvic, and distal lower limbs muscles, sparing ocular, bulbar, sphinc-
ter, respiratory, and cardiac muscles [1, 3, 6, 7, 13, 14]. Likewise, our patient’s clinical
features started with bilateral facial weakness which resulted in difficulty of closing his
eyes, whistling, and blowing chicks. Furthermore, progressive weakness and wasting of
shoulder, intercostal, and arm muscles resulted in scapular winging. In addition, pelvic
girdle muscles and distal legs muscles weakness resulted in waddling gait and foot
drops, respectively. Myopathic pattern, EMG findings, and normal or elevated serum CK
often support the diagnosis of FSHD [7]. Our patient’s EMG findings were suggestive
of myopathic pattern. However, the serum CK of our patient was normal, which could
be an expected possibility in patients with FSHD. Muscle biopsy is important in order
to support the diagnosis of FSHD in resource-limited areas like us. Histopathologi-
cal analysis from affected muscles could indicate angular muscle fibers atrophy and
scanty inflammatory cells, which will help us differentiate FSHD from other inflammatory
myopathies [1]. Therefore, the combination of clinico–pathological evidence and EMG
findings could be highly valuable in diagnosing muscular dystrophies such as FSHD in
resource-limited regions such as SSA. In the absence of supportive genetic evidence
for FSHD, it is important to rule out other dystrophies with similar clinical features such
as Emery–Dreifuss muscular dystrophy (EDMD), a slowly progressive X-linked muscular
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dystrophy with a late onset and a slightly reduced average lifespan [15]. The classic
overall triad of EDMD consists of early contractures, progressive muscle weakness and
atrophy, and cardiac abnormalities. The absence of muscular contracture and normal
cardiac function in our case makes the diagnosis of EDMD less likely.
Currently, the treatment options of FSHD are limited to symptomatic managements
such as relieving musculoskeletal pain, spine-alignment surgery, ankle prosthesis, and
nutritional advice [1, 5, 6]. Thus far, our patient was treated with analgesics for his
musculoskeletal pain, nutritional advice to increase his lean body mass, and ankle
prosthesis for his foot drops. Spine alignment surgery for Hyperlordosis was not done,
as the service was not available in Ethiopia. This case highlights the fact that a careful
clinical evaluation with thorough utilization of diagnostic investigations available at
our disposal may support the diagnosis of FSHD in resource-limited areas where the
necessary genetic tests are not available.
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